SME stock with a lot size of 4,000 shares: Pharma stock locked in 10% upper circuit; PAT jumps 67% in 9MFY26

On Thursday, shares of Sudarshan Pharma Industries Ltd hit a 10 per cent Upper Circuit to Rs 23.10 per share from its previous closing of Rs 21 per share. The stock’s 52-week high is Rs 38.71 per share while its 52-week low is Rs 18.50 per share. This pharma company’s stock falls under SME with a lot size of 4,000 shares. Currently at upper price band, the lot of 4,000 shares is trading at Rs 92,400.

Sudarshan Pharma Industries Ltd., incorporated in 2008, is a Mumbai-based company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical items, alongside trading in chemicals and solvents. They offer a diverse portfolio, from bulk chemicals and intermediates to finished formulations, with numerous products registered under their "R" trademark, including popular brands like Love Birds and Metfocal. The company operates both in India and international markets, including exports to countries in Southeast Asia, the Middle East and North Africa.

According to the Quarterly Results, the net sales increased by 16 per cent to Rs 168.01 crore in Q3FY26 compared to Q3FY25. The company reported a net profit of Rs 4.36 crore in Q3FY26, an increase of 51 per cent compared to Q3FY25. For nine-month results, the net sales increased by 40 per cent to Rs 482.14 crore and net profit increased by 67 per cent to Rs 12.58 crore in 9MFY26 compared to 9MFY25. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24.

Additionally, the company has expanded its global footprint by incorporating a wholly-owned subsidiary, Sudarshan Pharma Company Poland Limited Liability, in Warsaw. Following board approval in February 2025, the company invested PLN 5,000 for a 100 per cent stake, aiming to leverage this new entity to broaden its customer base within the European market. The subsidiary is set to specialise in the manufacture of chemicals, fertilisers, and plastics, as well as the wholesale of pharmaceutical products, positioning the parent company for significant industrial growth in the international chemical and agrochemical sectors.

The company has a market cap of over Rs 500 crore and has delivered a good profit growth of 70 per cent CAGR over the last 5 years. The stock is up by 25 per cent from its 52-week low of Rs 18.53 per share and has given multibagger returns of over 200 per cent in 2 years.

Disclaimer: The article is for informational purposes only and not investment advice.